Incendia Therapeutics
Biotechnology, 40 Guest St, Boston, , 2135, Massachusetts, United States, 11-50 Employees
Phone Number: 16*********
Who is INCENDIA THERAPEUTICS
Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers th...
Read More
-
Headquarters: 40 Guest St, Boston, Massachusetts, 2135, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from INCENDIA THERAPEUTICS
Incendia Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Incendia Therapeutics
Answer: Incendia Therapeutics's headquarters are located at 40 Guest St, Boston, , 2135, Massachusetts, United States
Answer: Incendia Therapeutics's phone number is 16*********
Answer: Incendia Therapeutics's official website is https://incendiatx.com
Answer: Incendia Therapeutics's revenue is Under $1 Million
Answer: Incendia Therapeutics's SIC: 2834
Answer: Incendia Therapeutics's NAICS: 325412
Answer: Incendia Therapeutics has 11-50 employees
Answer: Incendia Therapeutics is in Biotechnology
Answer: Incendia Therapeutics contact info: Phone number: 16********* Website: https://incendiatx.com
Answer: Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby punching holes in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month